BACKGROUND: Bacterial vaginosis (BV) is associated with an increased risk of high-risk human papillomavirus (hrHPV), whereas Lactobacillus-dominated vaginal microbiotas are associated with reduced burden of hrHPV. Few epidemiologic studies have prospectively investigated the relationships between vaginal bacteria and hrHPV, particularly among women from countries in Africa. METHODS: We conducted a prospective cohort study nested within the Preventing Vaginal Infections trial to evaluate associations between vaginal bacteria and hrHPV incidence and persistence. Sexually active, HIV-seronegative women aged 18 to 45 years who had a vaginal infection at screening were eligible to enroll. Analyses were restricted to participants enrolled in Kenya and randomized to placebo. At enrollment and months 2, 4, 6, 8, 10, and 12, hrHPV testing, quantitative polymerase chain reaction (measuring taxon quantity per swab), and 16S rRNA gene amplicon sequencing of the vaginal microbiota were performed. Generalized estimating equations multinomial logistic regression models were fit to evaluate associations between vaginal bacteria and incident and persistent hrHPV. RESULTS: Eighty-four participants were included in this analysis. Higher concentrations of Lactobacillus crispatus were inversely associated with persistent hrHPV detection. Specifically, 1 tertile higher L. crispatus concentration was associated with 50% reduced odds of persistent hrHPV detection (odds ratio, 0.50; 95% confidence interval, 0.29-0.85). CONCLUSIONS: This study is consistent with reports that vaginal L. crispatus is associated with reduced susceptibility to hrHPV persistence. Evidence from in vitro studies provides insight into potential mechanisms by which L. crispatus may mediate hrHPV risk. Future studies should further explore in vivo mechanisms that may drive this relationship and opportunities for intervention.
BACKGROUND: Bacterial vaginosis (BV) is associated with an increased risk of high-risk human papillomavirus (hrHPV), whereas Lactobacillus-dominated vaginal microbiotas are associated with reduced burden of hrHPV. Few epidemiologic studies have prospectively investigated the relationships between vaginal bacteria and hrHPV, particularly among women from countries in Africa. METHODS: We conducted a prospective cohort study nested within the Preventing Vaginal Infections trial to evaluate associations between vaginal bacteria and hrHPV incidence and persistence. Sexually active, HIV-seronegative women aged 18 to 45 years who had a vaginal infection at screening were eligible to enroll. Analyses were restricted to participants enrolled in Kenya and randomized to placebo. At enrollment and months 2, 4, 6, 8, 10, and 12, hrHPV testing, quantitative polymerase chain reaction (measuring taxon quantity per swab), and 16S rRNA gene amplicon sequencing of the vaginal microbiota were performed. Generalized estimating equations multinomial logistic regression models were fit to evaluate associations between vaginal bacteria and incident and persistent hrHPV. RESULTS: Eighty-four participants were included in this analysis. Higher concentrations of Lactobacillus crispatus were inversely associated with persistent hrHPV detection. Specifically, 1 tertile higher L. crispatus concentration was associated with 50% reduced odds of persistent hrHPV detection (odds ratio, 0.50; 95% confidence interval, 0.29-0.85). CONCLUSIONS: This study is consistent with reports that vaginal L. crispatus is associated with reduced susceptibility to hrHPV persistence. Evidence from in vitro studies provides insight into potential mechanisms by which L. crispatus may mediate hrHPV risk. Future studies should further explore in vivo mechanisms that may drive this relationship and opportunities for intervention.
Authors: Jennifer E Balkus; Sujatha Srinivasan; Omu Anzala; Joshua Kimani; Chloe Andac; Jane Schwebke; David N Fredricks; R Scott McClelland Journal: J Infect Dis Date: 2017-03-01 Impact factor: 5.226
Authors: Laura L Reimers; Supriya D Mehta; L Stewart Massad; Robert D Burk; Xianhong Xie; Jacques Ravel; Mardge H Cohen; Joel M Palefsky; Kathleen M Weber; Xiaonan Xue; Kathryn Anastos; Howard Minkoff; Jessica Atrio; Gypsyamber D'Souza; Qian Ye; Christine Colie; Christine P Zolnik; Gregory T Spear; Howard D Strickler Journal: J Infect Dis Date: 2016-08-11 Impact factor: 5.226
Authors: F Xavier Bosch; Ann N Burchell; Mark Schiffman; Anna R Giuliano; Silvia de Sanjose; Laia Bruni; Guillermo Tortolero-Luna; Susanne Kruger Kjaer; Nubia Muñoz Journal: Vaccine Date: 2008-08-19 Impact factor: 3.641
Authors: Sujatha Srinivasan; Noah G Hoffman; Martin T Morgan; Frederick A Matsen; Tina L Fiedler; Robert W Hall; Frederick J Ross; Connor O McCoy; Roger Bumgarner; Jeanne M Marrazzo; David N Fredricks Journal: PLoS One Date: 2012-06-18 Impact factor: 3.240
Authors: Siddhartha Mandal; Will Van Treuren; Richard A White; Merete Eggesbø; Rob Knight; Shyamal D Peddada Journal: Microb Ecol Health Dis Date: 2015-05-29
Authors: A Mitra; D A MacIntyre; Y S Lee; A Smith; J R Marchesi; B Lehne; R Bhatia; D Lyons; E Paraskevaidis; J V Li; E Holmes; J K Nicholson; P R Bennett; M Kyrgiou Journal: Sci Rep Date: 2015-11-17 Impact factor: 4.379
Authors: Anita Mitra; David A MacIntyre; George Ntritsos; Ann Smith; Konstantinos K Tsilidis; Julian R Marchesi; Phillip R Bennett; Anna-Barbara Moscicki; Maria Kyrgiou Journal: Nat Commun Date: 2020-04-24 Impact factor: 14.919
Authors: Elisabeth McClymont; Arianne Y Albert; Christine Wang; Scott J Dos Santos; François Coutlée; Marette Lee; Sharon Walmsley; Nancy Lipsky; Mona Loutfy; Sylvie Trottier; Fiona Smaill; Marina B Klein; Mark H Yudin; Marianne Harris; Wendy Wobeser; Janet E Hill; Deborah M Money Journal: Int J STD AIDS Date: 2022-07-01 Impact factor: 1.456